Douglas Lane & Associates LLC Sells 1,910 Shares of Danaher Corporation $DHR

Key Points

• Douglas Lane & Associates LLC reduced its stake in Danaher Corporation by 0.5%, owning a total of 349,127 shares worth approximately $68.97 million as of its latest SEC filing.
• Multiple large investors, including Vanguard Group and Invesco Ltd., have increased their stakes in Danaher, reflecting positive sentiment in the market.
• Danaher recently announced a quarterly dividend of $0.32 per share, with a scheduled payment date of October 31st, representing an annual yield of 0.7%.

Douglas Lane & Associates LLC reduced its stake in Danaher Corporation (NYSE:DHR - Free Report) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 349,127 shares of the conglomerate's stock after selling 1,910 shares during the quarter. Douglas Lane & Associates LLC's holdings in Danaher were worth $68,967,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Hills Bank & Trust Co raised its stake in Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after purchasing an additional 53 shares in the last quarter. Sageworth Trust Co raised its stake in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares in the last quarter. 1834 Investment Advisors Co. raised its stake in Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after purchasing an additional 54 shares in the last quarter. Rakuten Securities Inc. raised its stake in Danaher by 33.3% in the first quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after purchasing an additional 56 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC raised its stake in shares of Danaher by 1.6% during the first quarter. Kingswood Wealth Advisors LLC now owns 3,466 shares of the conglomerate's stock worth $710,000 after acquiring an additional 56 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on DHR shares. Guggenheim reissued a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, Barclays reissued an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average target price of $246.35.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.20% of the stock is currently owned by company insiders.

Danaher Trading Up 1.0%

Shares of NYSE DHR traded up $1.89 during mid-day trading on Tuesday, hitting $190.43. The stock had a trading volume of 4,817,643 shares, compared to its average volume of 3,203,970. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The business has a 50 day moving average price of $200.77 and a two-hundred day moving average price of $198.59. The firm has a market cap of $136.36 billion, a P/E ratio of 40.52, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's payout ratio is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.